ChromaDex Supports the US Military with its Industry Leading NAD+ Supplement, Tru Niagen®
- None.
- None.
Insights
ChromaDex Corp.'s recent announcement regarding the adoption of Tru Niagen by the US Military Special Operations Forces could be indicative of potential growth in institutional sales. Tru Niagen's exclusive military program may lead to a stable and recurring revenue stream, which is a positive signal for investors. The program demonstrates the company's ability to penetrate high-value markets and may enhance brand credibility. However, the financial impact will depend on the scale of the adoption and the terms of the agreement, which are not disclosed.
Investors should monitor the company's future financial disclosures for specific sales figures related to this initiative. Increased sales to the military could improve the company's overall financial health if the margins on these sales are favorable. It is also important to consider the potential for expanded use within the military or similar institutional adoption as a catalyst for long-term growth.
From a medical research perspective, the efficacy of Tru Niagen in improving cellular health through NAD+ supplementation is noteworthy. Its clinical backing and certifications, like NSF for Sport, suggest a high-quality, rigorously tested product. The adoption by the US Military adds a layer of validation to its claims, potentially influencing consumer perception and trust in the supplement. However, it is essential to scrutinize ongoing and future clinical studies to ensure the claims of efficacy remain evidence-based and that any long-term health impacts are well-understood.
Stakeholders should consider the potential for increased research and development costs associated with maintaining this gold standard and the implications of any regulatory changes on the supplement industry.
The health and wellness supplement industry is highly competitive, with a continuous need for innovation and scientific validation. ChromaDex's focus on NAD+ research and its patented nicotinamide riboside technology positions the company at the forefront of the cellular health segment. The partnership with the US Military could serve as a powerful marketing tool, potentially influencing consumer behavior and increasing market share.
However, competitors may respond with their initiatives and the market should observe how ChromaDex maintains its competitive edge. Additionally, the reliance on scientific endorsements and certifications is critical in this industry and any compromise in these areas could negatively impact the company's reputation and market position.
Tru Niagen is now available to US troops through an exclusive Military program
As the most efficient, studied, and high-quality NAD+ boosting supplement on the market, ChromaDex’s patented nicotinamide riboside (NR) supplement, Tru Niagen®, is now being utilized by US Military Special Operations Forces, marking a significant milestone in the product's journey toward promoting cellular health and resilience. In a gesture of gratitude and further support US troops, ChromaDex has launched an exclusive program that offers Tru Niagen products to active and veteran Military Service Members. This initiative reflects ChromaDex’s commitment to the health and well-being of those who serve the Nation.
NAD+ is an essential coenzyme vital for cellular health and NR is the most efficient way to elevate NAD+ levels due to its ability to cross directly through the cell membrane. Clinically proven to safely and effectively increase NAD+, Tru Niagen supports cellular energy, combats physiological stress, and aids in cellular repair and recovery – all of which are vital for the physically demanding environments encountered in military operations.
"We are honored that Tru Niagen will play a role in the health and wellness of our troops,” said Rob Fried, CEO of ChromaDex. “This further underscores the significance of NAD+ in physically demanding professions."
As the gold standard NAD+ boosting supplement, Tru Niagen embodies the highest scientific rigor and quality standards and is backed by two Nobel Prize winners, 30+ human clinical studies, 300 published scientific studies, and accepted by the world’s most rigorous regulatory bodies. Tru Niagen products are certified by NSF for Sport, Alkemist Labs, Star-K (Kosher), and IFANCA (Halal) and every lot of Tru Niagen is tested for potency, safety, and purity. Certificates of analysis are readily available so each bottle can be traced directly to ChromaDex’s ISO/IEC 17025:2017 accredited laboratory.
"As a clinician focused on the nexus of health and performance, I recognize the paramount importance of cellular health and mitochondrial optimization. This is particularly true in high-stress, physically demanding environments like those faced by military personnel. Tru Niagen stands out as the leading, gold-standard NAD+ supplement in this regard. Its ability to effectively boost NAD+ levels and support mitochondrial function is crucial for maintaining cellular resilience, energy metabolism, and overall cellular repair. Further, it features patented nicotinamide riboside (NR), which is the most efficient NAD+ precursor available. These benefits are essential for military members who regularly encounter extreme physical and psychological stress. Incorporating Tru Niagen into their regimen can be a game-changer in optimizing their performance and recovery, ensuring they are always mission-ready," remarked Dr. Jim Lavalle, Clinical Pharmacist, CEO of Metabolic Code Enterprises, and ChromaDex Consultant.
This initiative highlights ChromaDex's dedication to continuing to pioneer NAD+ research and its commitment to providing high-quality, science-backed products. As the leading NAD+ boosting supplement available, Tru Niagen has already made a significant impact on the health and wellness industry, and its adoption by the US Military is a testament to its effectiveness, quality, and reliability.
For more information about Tru Niagen’s military discount program, please visit https://discover.truniagen.com/military/. If you are an active or veteran US Military Service Member interested in purchasing Tru Niagen, please email military@chromadex.com for more details.
About ChromaDex:
ChromaDex Corp. is a global bioscience company dedicated to healthy aging. The ChromaDex team, which includes world-renowned scientists, is pioneering research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. ChromaDex is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen®. Nicotinamide riboside and other NAD+ precursors are protected by ChromaDex’s patent portfolio. ChromaDex maintains a website at www.chromadex.com to which ChromaDex regularly posts copies of its press releases as well as additional and financial information about the Company.
Forward-Looking Statements:
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, including statements related to incorporating Tru Niagen into the regimen of the military personnel can be a game-changer in optimizing their performance and recovery. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects," "anticipates," "intends," "estimates," "plans," "potential," "possible," "probable," "believes," "seeks," "may," "will," "should," "could" or the negative of such terms or other similar expressions. Risks that contribute to the uncertain nature of these forward-looking statements include the impact of the COVID-19 pandemic on our business and the global economy; our history of operating losses and need to obtain additional financing; the growth and profitability of our product sales; our ability to maintain sales, marketing and distribution capabilities; changing consumer perceptions of our products; our reliance on a single or limited number of third-party suppliers; and the risks and uncertainties associated with our business and financial condition. More detailed information about ChromaDex and the risk factors that may affect the realization of forward-looking statements is set forth in ChromaDex's Annual Report on Form 10-K for the fiscal year ended December 31, 2022, ChromaDex's Quarterly Reports on Form 10-Q and other filings submitted by ChromaDex to the SEC, copies of which may be obtained from the SEC's website at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and actual results may differ materially from those suggested by these forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement and ChromaDex undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231220875928/en/
ChromaDex Media Contact:
Kendall Knysch, Head of Media Relations & Partnerships
310-388-6706 ext. 689
kendall.knysch@chromadex.com
ChromaDex Investor Relations Contact:
+1 (949) 356-1620
InvestorRelations@ChromaDex.com
Source: ChromaDex Corporation
FAQ
What is the company launching for the US Military?
What is the significance of Tru Niagen for US troops?
Who is the CEO of ChromaDex Corp.?
What is the scientific backing for Tru Niagen?
What certifications does Tru Niagen have?
